Investor News & Events

Press Releases

June 25, 2025

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Read the Press Release

June 23, 2025

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma

Read the Press Release

June 20, 2025

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Read the Press Release

See more press releases

Upcoming Events

31Jul

2025

Second Quarter 2025

Second quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation will be followed by a Q&A session.

15:00 - 16:30 CET (9:00am – 10:30am EDT)

Quarterly results

24Oct

2025

Third Quarter 2025

Third quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation will be followed by a Q&A session.

14:30 - 16:00 CET (8:30am – 10am EDT)

Quarterly results

See all upcoming events

Past Events

24Apr

2025

First quarter 2025

First quarter 2025 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.

Quarterly results

Discover more

30Jan

2025

Fourth Quarter & Full Year 2024 Results

Fourth quarter and full year 2024 results were reviewed by management during a live audio webcast with the financial community on January 30, 2025. The presentation was followed by a Q&A session.

15:00 - 16:30 CET (9:00am – 10:30am EST)

Quarterly results

Discover more

25Oct

2024

Third quarter 2024 results

Third quarter 2024 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session.

14:00 - 15:30 CET (8:00am – 9:30am EST)

Quarterly results

Discover more